^
BIOMARKER:

HER-2 overexpression

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
lapatinib
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Negative Breast Cancer
trastuzumab + lapatinib
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
lapatinib
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
trastuzumab
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
trastuzumab/hyaluronidase-oysk
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
trastuzumab + docetaxel
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Esophageal Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
HER-2 overexpression
Gastric Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
HER-2 overexpression
Esophageal Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
HER-2 overexpression
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
HER-2 overexpression
Gastric Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
HER-2 overexpression
Gastric Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A2 - Guideline
HER-2 overexpression
Esophageal Cancer
pembrolizumab + trastuzumab
Sensitive: A2 - Guideline
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A2 - Guideline
HER-2 overexpression
Gastric Cancer
lapatinib
Sensitive: B - Late Trials
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: B - Late Trials
HER-2 overexpression
HER2 Positive Breast Cancer
lapatinib
Sensitive: B - Late Trials
HER-2 overexpression
Solid Tumor
CT-0508
Sensitive: B - Late Trials
HER-2 overexpression
Gallbladder Cancer
trastuzumab
Sensitive: C1 - Off-label
HER-2 overexpression
Endometrial Adenocarcinoma
trastuzumab
Sensitive: C1 - Off-label
HER-2 overexpression
Endometrial Cancer
trastuzumab
Sensitive: C1 - Off-label
HER-2 overexpression
Esophageal Cancer
trastuzumab
Sensitive: C1 - Off-label
HER-2 overexpression
Pancreatic Cancer
trastuzumab
Sensitive: C1 - Off-label
HER-2 overexpression
Salivary Gland Cancer
trastuzumab
Sensitive: C1 - Off-label
HER-2 overexpression
Cervical Cancer
trastuzumab
Resistant: C1 - Off-label
HER-2 overexpression
Urothelial Cancer
trastuzumab
Sensitive: C1 - Off-label
HER-2 overexpression
Gastric Cancer
ASLAN001
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
Salivary Gland Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
Gastric Cancer
disitamab vedotin
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
Breast Cancer
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
HER2 Positive Breast Cancer
HM 78136B
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
Gastric Cancer
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
Gastric Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
NSCLC
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Her-VAXX
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
Urothelial Cancer
disitamab vedotin
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
Breast Cancer
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
Biliary Tract Cancer
ZW25
Sensitive: C3 – Early Trials
HER-2 overexpression
CRC
cetuximab
Sensitive: C3 – Early Trials
HER-2 overexpression
Solid Tumor
KN046 + KN026
Sensitive: C3 – Early Trials
HER-2 overexpression
GastroEsophageal Cancer
disitamab vedotin
Sensitive: C3 – Early Trials
HER-2 overexpression
Gastric Cancer
cabazitaxel
Sensitive: C3 – Early Trials
HER-2 overexpression
Esophageal Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 overexpression
Endometrial Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 overexpression
Ovarian Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 overexpression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
HER-2 overexpression
NSCLC
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 overexpression
Pancreatic Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 overexpression
Bladder Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 overexpression
CRC
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 overexpression
Salivary Gland Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 overexpression
HER2 Positive Breast Cancer
ZW25
Sensitive: C3 – Early Trials
HER-2 overexpression
GastroEsophageal Cancer
ZW25
Sensitive: C3 – Early Trials
HER-2 overexpression
Gastric Cancer
AT101
Sensitive: C3 – Early Trials
HER-2 overexpression
CRC
EGFR inhibitor
Resistant: C3 – Early Trials
HER-2 overexpression
Breast Cancer
simvastatin
Sensitive: C3 – Early Trials
HER-2 overexpression
Uterine Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 overexpression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab + MCLA-128
Sensitive: C3 – Early Trials
HER-2 overexpression
LUAD
ado-trastuzumab emtansine
Sensitive: C4 – Case Studies